Keywords: amgen, aranesp, gives, response, mds, biotechnology, major

Amgen's Aranesp gives 77% response in MDS

Article | 18 July 2005

Print This

US biotechnology major Amgen says that new interim data from a Phase II study evaluating the use of Aranesp (darbepoetin ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in